ATE218342T1 - Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen - Google Patents

Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen

Info

Publication number
ATE218342T1
ATE218342T1 AT98101081T AT98101081T ATE218342T1 AT E218342 T1 ATE218342 T1 AT E218342T1 AT 98101081 T AT98101081 T AT 98101081T AT 98101081 T AT98101081 T AT 98101081T AT E218342 T1 ATE218342 T1 AT E218342T1
Authority
AT
Austria
Prior art keywords
cryptosporidiosis
rifaximin
treatment
medication
diarrhea caused
Prior art date
Application number
AT98101081T
Other languages
English (en)
Inventor
Patrizio Ferrari
Antonella Ferrieri
Pietro Caramello
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of ATE218342T1 publication Critical patent/ATE218342T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98101081T 1997-02-14 1998-01-22 Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen ATE218342T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (1)

Publication Number Publication Date
ATE218342T1 true ATE218342T1 (de) 2002-06-15

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98101081T ATE218342T1 (de) 1997-02-14 1998-01-22 Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen

Country Status (12)

Country Link
US (1) US5886002A (de)
EP (1) EP0858804B1 (de)
JP (1) JP4848083B2 (de)
KR (1) KR100436243B1 (de)
CN (1) CN1115146C (de)
AT (1) ATE218342T1 (de)
DE (1) DE69805672T2 (de)
DK (1) DK0858804T3 (de)
ES (1) ES2178048T3 (de)
HU (1) HU224592B1 (de)
IT (1) IT1290679B1 (de)
PT (1) PT858804E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
AU2004236173B2 (en) * 2003-04-30 2008-07-03 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN104382900A (zh) * 2006-08-02 2015-03-04 萨利克斯药品公司 治疗放射性肠炎的组合物和方法
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) * 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
WO2016138118A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals
JP6817966B2 (ja) * 2015-06-10 2021-01-20 シンロジック オペレーティング カンパニー インコーポレイテッド 高アンモニア血症に関連する疾患を治療するために操作された細菌
US11224591B2 (en) 2016-10-14 2022-01-18 Cipla Limited Pharmaceutical compositions comprising rifaximin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
ITBO970064A0 (it) 1997-02-14
JPH10226645A (ja) 1998-08-25
ES2178048T3 (es) 2002-12-16
KR19980071348A (ko) 1998-10-26
EP0858804B1 (de) 2002-06-05
DE69805672D1 (de) 2002-07-11
KR100436243B1 (ko) 2004-08-25
JP4848083B2 (ja) 2011-12-28
IT1290679B1 (it) 1998-12-10
HUP9800115A1 (hu) 1999-06-28
HU224592B1 (hu) 2005-11-28
US5886002A (en) 1999-03-23
ITBO970064A1 (it) 1998-08-14
DK0858804T3 (da) 2002-07-08
DE69805672T2 (de) 2003-01-23
HU9800115D0 (en) 1998-03-30
EP0858804A1 (de) 1998-08-19
PT858804E (pt) 2002-10-31
CN1214244A (zh) 1999-04-21
HUP9800115A3 (en) 2000-04-28
CN1115146C (zh) 2003-07-23

Similar Documents

Publication Publication Date Title
ATE218342T1 (de) Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen
DE69635959D1 (de) Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
DE69429717D1 (de) Heterocyclische verbindungen und ihre herstellung und verwendung
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
ATE480235T1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
MA27113A1 (fr) Activateurs de glucokinase oxygenes cycloalkyle ou substitues cycloalkyle
MY131458A (en) Pyrolopyrimidine compounds
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR200000197T2 (tr) Yeni bileşimler
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
ES2177581T3 (es) Uso de compuestos de piperidina en el tratamiento de esquizofrenia.
TNSN98210A1 (fr) Trifluoromethylethers cycliques a fonction piperidinylaminomethyle, procede pour leur preparation et compositions pharmaceutiques les contenant
IL104261A0 (en) Azacyclic and azabicyclic compounds,their preparation and pharmaceutical compositions containing them
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
ATE235244T1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
TR199700999T1 (xx) Askomisinler.
MA27905A1 (fr) Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification